SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
$PTPI
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
Delivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong Cash Flows and Sustainable Margins, Resulting in Superior Value Creation for Shareholders Introduces Diverse Slate with Expertise in Corporate Governance, Ecommerce, Finance, M&A and Strategic Growth Across Relevant B2B and B2C Categories Steven Urvan (together with the other participants in his solicitation, the "Urvan Group" or "we"), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ:POWW) ("AMMO" or the "Co
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021. Recent Corporate Highlights: Entered collaboration with Dr. Drew Pinsky to bring awareness to men's health with a focus on driving awareness around erectile and other sexual dysfunctionsPartnered with leading global contract manufacturer to bring production of erectile dysfunction drug STENDRA® to the United StatesLaunched two self-selection studies for erectile dysfunction drug STENDRA®Announced positive over-the-counter (OTC) label compr
Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Comp
Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. If this Software as a Service ("SaaS") and S
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored >80% compreh
S-1 - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
SC 13G - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor